1.
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next
generation. Cell 144: 646–674, 2011.
2.
Fearon, E. R. & Vogelstein, B. A genetic model for colorectal
tumorigenesis. Cell 61: 759–767, 1990.
3.
Soda, M. et al. Identification of the transforming EML4-ALK fusion
gene in non-small-cell lung cancer. Nature 448: 561–566, 2007.
4.
Arai, Y. et al. Fibroblast growth factor receptor 2 tyrosine kinase
fusions define a unique molecular subtype of cholangiocarcinoma.
Hepatology 59: 1427–1434, 2014.
5.
Shih, C., Shilo, B.-Z., Goldfarb, M. P., Dannenberg, A. & Weinberg, R.
A. Passage of phenotypes of chemically transformed cells via
transfection of DNA and chromatin. Cell Biol. 76: 5714–5718, 1979.
75
6.
Nagy, A. Cre recombinase: the universal reagent for genome tailoring.
Genesis 26: 99–109, 2000.
7.
Deng, C. X. Conditional knockout mouse models of cancer. Cold Spring
Harb. Protoc. 2014: 1217–1233, 2014.
8.
Sato, T. et al. Single Lgr5 stem cells build crypt-villus structures in
vitro without a mesenchymal niche. Nature 459: 262–265, 2009.
9.
Onuma, K. et al. Genetic reconstitution of tumorigenesis in primary
intestinal cells. Proc. Natl. Acad. Sci. 110: 11127–11132, 2013.
10.
Maru, Y., Orihashi, K. & Hippo, Y. Lentivirus-Based Stable Gene
Delivery into Intestinal Organoids. Methods Mol. Biol. 1422: 13–21,
2016.
11.
Maru, Y., Onuma, K., Ochiai, M., Imai, T. & Hippo, Y. Shortcuts to
intestinal carcinogenesis by genetic engineering in organoids. Cancer
76
Sci. 110: 858–866, 2019.
12.
Patel, T. Worldwide trends in mortality from biliary tract
malignancies. BMC Cancer 2: 10, 2002.
13.
Tyson, G. L. & El-Serag, H. B. Risk factors for cholangiocarcinoma.
Hepatology 54: 173–184, 2011.
14.
Rizvi, S. & Gores, G. J. Pathogenesis, Diagnosis, and Management of
Cholangiocarcinoma. Gastroenterology 145: 1215–1229, 2013.
15.
Misra, S., Chaturvedi, A., Misra, N. C. & Sharma, I. D. Carcinoma of
the gallbladder. Lancet Oncol. 4: 167–176, 2003.
16.
Razumilava, N. & Gores, G. J. Cholangiocarcinoma. Lancet 383: 2168–
2179, 2014.
17.
Nakamura, H. et al. Genomic spectra of biliary tract cancer. Nat.
77
Genet. 47: 1003–1010, 2015.
18.
Zou, S. et al. Mutational landscape of intrahepatic
cholangiocarcinoma. Nat. Commun. 5: 5696, 2014.
19.
O’Dell, M. R. et al. Kras(G12D) and p53 Mutation Cause Primary
Intrahepatic Cholangiocarcinoma. Cancer Res. 72: 1557–1567, 2012.
20.
Ikenoue, T. et al. A novel mouse model of intrahepatic
cholangiocarcinoma induced by liver-specific Kras activation and Pten
deletion. Sci. Rep. 6: 23899, 2016.
21.
Xu, X. et al. Induction of intrahepatic cholangiocellular carcinoma by
liver-specific disruption of Smad4 and Pten in mice. J. Clin. Invest.
116: 1843–1852, 2006.
22.
Zender, S. et al. A critical role for notch signaling in the formation of
cholangiocellular carcinomas. Cancer Cell 23: 784–795, 2013.
78
23.
Lee, K.-P. et al. The Hippo-Salvador pathway restrains hepatic oval
cell proliferation, liver size, and liver tumorigenesis. Proc. Natl. Acad.
Sci. 107: 8248–8253, 2010.
24.
Marsh, V., Davies, E. J., Williams, G. T. & Clarke, A. R. PTEN loss
and KRAS activation cooperate in murine biliary tract malignancies.
J. Pathol. 230: 165–173, 2013.
25.
Kiguchi, K. et al. Constitutive expression of ErbB-2 in gallbladder
epithelium results in development of adenocarcinoma. Cancer Res. 61:
6971–6976, 2001.
26.
Ochiai, M. et al. Kras-driven heterotopic tumor development from
hepatobiliary organoids. Carcinogenesis 40: 1142–1152, 2019.
27.
Morita, S., Kojima, T. & Kitamura, T. Plat-E: an efficient and stable
system for transient packaging of retroviruses. Gene Ther. 7: 1063–
1066, 2000.
79
28.
Adams, J. R. et al. Cooperation between Pik3ca and p53 mutations in
mouse mammary tumor formation. Cancer Res. 71: 2706–2717, 2011.
29.
Jackson, E. L. Analysis of lung tumor initiation and progression using
conditional expression of oncogenic K-ras. Genes Dev. 15: 3243–3248,
2001.
30.
Marino, S., Vooijs, M., Van Der Gulden, H., Jonkers, J. & Berns, A.
Induction of medulloblastomas in p53-null mutant mice by somatic
inactivation of Rb in the external granular layer cells of the
cerebellum. Genes Dev. 14: 994–1004, 2000.
31.
Katayanagi, K., Kono, N. & Nakanuma, Y. Isolation, culture and
characterization of biliary epithelial cells from different anatomical
levels of the intrahepatic and extrahepatic biliary tree from a mouse.
Liver 18: 90–98, 1998.
32.
Tanimizu, N. Notch signaling controls hepatoblast differentiation by
80
altering the expression of liver-enriched transcription factors. J. Cell
Sci. 117: 3165–3174, 2004.
33.
Lemaigre, F. P. Mechanisms of Liver Development: Concepts for
Understanding Liver Disorders and Design of Novel Therapies.
Gastroenterology 137: 62–79, 2009.
34.
Tannapfel, A. et al. Frequency of p16(INK4A) alterations and K-ras
mutations in intrahepatic cholangiocarcinoma of the liver. Gut 47:
721–727, 2000.
35.
Gysin, S., Salt, M., Young, A. & McCormick, F. Therapeutic strategies
for targeting ras proteins. Genes Cancer 2: 359–72, 2011.
36.
Ong, C. K. et al. Exome sequencing of liver fluke–associated
cholangiocarcinoma. Nat. Genet. 44: 690–693, 2012.
37.
Wotton, S. F. et al. RUNX1 transformation of primary embryonic
81
fibroblasts is revealed in the absence of p53. Oncogene 23: 5476–5486,
2004.
38.
Li, M. et al. Whole-exome and targeted gene sequencing of gallbladder
carcinoma identifies recurrent mutations in the ErbB pathway. Nat.
Genet. 46: 872–876, 2014.
39.
Noguchi, R. et al. Genetic alterations in Japanese extrahepatic biliary
tract cancer. Oncol. Lett. 14: 877–884, 2017.
40.
Hanada, K. et al. Gene mutations of K-ras in gallbladder mucosae and
gallbladder carcinoma with an anomalous junction of the
pancreaticobiliary duct. Am. J. Gastroenterol. 94: 1638–1642, 1999.
41.
Matsubara, T. et al. K-ras point mutations in cancerous and
noncancerous biliary epithelium in patients with pancreaticobiliary
maljunction. Cancer 77: 1752–1757, 1996.
82
42.
Zen, Y. et al. Biliary intraepithelial neoplasia: An international
interobserver agreement study and proposal for diagnostic criteria.
Mod. Pathol. 20: 701–709, 2007.
43.
Zen, Y. et al. Biliary papillary tumors share pathological features with
intraductal papillary mucinous neoplasm of the pancreas. Hepatology
44: 1333–1343, 2006.
44.
Li, X. et al. Co-activation of PIK3CA and Yap promotes development of
hepatocellular and cholangiocellular tumors in mouse and human
liver. Oncotarget 6: 10102–10115, 2015.
45.
Fan, B. et al. Cholangiocarcinomas can originate from hepatocytes in
mice. J. Clin. Invest. 122: 2911–2915, 2012.
83
...
論文の公開元へ
